Literature DB >> 16241954

Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity.

M R Barnard1, M D Linden, A L Frelinger, Y Li, M L Fox, M I Furman, A D Michelson.   

Abstract

BACKGROUND: Monocytes and neutrophils form heterotypic aggregates with platelets initially via engagement of platelet surface P-selectin with leukocyte surface P-selectin glycoprotein ligand-1 (PSGL-1). The resultant intracellular signaling causes the leukocyte surface expression of tissue factor and activation of leukocyte surface Mac-1 (integrin alphaMbeta2, CD11b/CD18). The activation-dependent conformational change in monocyte surface Mac-1 results in the binding of coagulation factor Xa (FXa) and/or fibrinogen to Mac-1. The aim of this study was to develop whole blood flow cytometry assays of these procoagulant activities and to investigate the effects of platelet binding to monocytes and neutrophils.
METHODS: Citrate or D-Phe-Pro-Arg-chloromethylketone (PPACK) anticoagulated whole blood was incubated with monoclonal antibodies against CD14 (PECy5), CD42a (PE), FITC-conjugated test antibody and an agonist, and then fixed with FACS lyse. Appropriate isotype negative controls were prepared in parallel. A BD FACSCalibur was used to analyze monocytes and neutrophils, which were identified based on CD14 fluorescence, forward and 90 degrees light scatter. These populations were further gated into CD42a-positive (platelet-bound) and CD42a-negative (platelet-free). Geometric mean fluorescence and per cent positive data were collected for each subpopulation to measure the binding of test antibodies directed at CD42a, tissue factor, coagulation FXa, bound fibrinogen, activated Mac-1, and CD11b. Compensation controls were prepared on six normal donors prior to the study and these settings were used throughout the 10 donor study. Negative controls verified the lack of cross talk, particularly in the quantified FITC and PE parameters.
RESULTS: The physiologic agonists collagen and ADP increased monocyte-platelet and neutrophil-platelet aggregates and increased leukocyte surface Mac-1/CD11b and surface-bound tissue factor, FXa and fibrinogen. Whereas the increases in Mac-1/CD11b were mainly independent of leukocyte-platelet binding, the increases in surface-bound tissue factor, FXa and fibrinogen were mainly dependent on leukocyte-platelet binding.
CONCLUSIONS: (i) We have developed novel whole blood flow cytometry assays to measure bound tissue factor, coagulation FXa, fibrinogen, activated Mac-1 and CD11b on the surface of monocytes and neutrophils, allowing independent analysis of monocytes and neutrophils with and without surface-adherent platelets. (ii) The monocyte and neutrophil surface binding of tissue factor, FXa and fibrinogen is mainly dependent on platelet adherence to monocytes and neutrophils, whereas the monocyte and neutrophil surface expression of CD11b and activated Mac-1 is mainly independent of platelet adherence to monocytes and neutrophils.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16241954     DOI: 10.1111/j.1538-7836.2005.01603.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  17 in total

1.  Circulating platelet and neutrophil activation correlates with the clinical course of unstable angina.

Authors:  Satoshi Murasaki; Kagari Murasaki; Kenjiro Tanoue; Masatoshi Kawana; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  Heart Vessels       Date:  2007-11-26       Impact factor: 2.037

Review 2.  Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum.

Authors:  Adriana Vieira-de-Abreu; Robert A Campbell; Andrew S Weyrich; Guy A Zimmerman
Journal:  Semin Immunopathol       Date:  2011-08-06       Impact factor: 9.623

Review 3.  Platelets as cellular effectors of inflammation in vascular diseases.

Authors:  Matthew T Rondina; Andrew S Weyrich; Guy A Zimmerman
Journal:  Circ Res       Date:  2013-05-24       Impact factor: 17.367

Review 4.  The Function and Regulation of Platelet P2Y12 Receptor.

Authors:  Xiaohua Li; Guoxing Zhang; Xia Cao
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-28       Impact factor: 3.727

5.  Developmental endothelial locus-1 modulates platelet-monocyte interactions and instant blood-mediated inflammatory reaction in islet transplantation.

Authors:  Ioannis Kourtzelis; Klara Kotlabova; Jong-Hyung Lim; Ioannis Mitroulis; Anaisa Ferreira; Lan-Sun Chen; Bettina Gercken; Anja Steffen; Elisabeth Kemter; Anne Klotzsche-von Ameln; Claudia Waskow; Kavita Hosur; Antonios Chatzigeorgiou; Barbara Ludwig; Eckhard Wolf; George Hajishengallis; Triantafyllos Chavakis
Journal:  Thromb Haemost       Date:  2015-12-17       Impact factor: 5.249

6.  Predicting significance of COX-2 expression of peripheral blood monocyte in patients with coronary artery disease.

Authors:  Qinghua Huang; Xianming Fei; Shengbing Li; Chan Xu; Chunping Tu; Lei Jiang; Mingyi Wo
Journal:  Ann Transl Med       Date:  2019-09

7.  First report of elevated monocyte-platelet aggregates in healthy children.

Authors:  Christina Yip; Vera Ignjatovic; Chantal Attard; Paul Monagle; Matthew D Linden
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

Review 8.  Platelet function tests: a comparative review.

Authors:  Rita Paniccia; Raffaella Priora; Agatina Alessandrello Liotta; Rosanna Abbate
Journal:  Vasc Health Risk Manag       Date:  2015-02-18

Review 9.  Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications.

Authors:  Katalin Koltai; Gabor Kesmarky; Gergely Feher; Antal Tibold; Kalman Toth
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

10.  P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.

Authors:  Michelle A Berny-Lang; Joseph A Jakubowski; Atsuhiro Sugidachi; Marc R Barnard; Alan D Michelson; Andrew L Frelinger
Journal:  J Am Heart Assoc       Date:  2013-05-15       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.